Chimerix Inc Reports Fourth Quarter and Full-Year 2023 Financial Results
Operational Progress and Financial Highlights
Source: yahoo.com
Stay updated with breaking news from 24 2023. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operational Progress and Financial Highlights
Challenges Persist as PTVE Navigates Market Headwinds and Restructuring Efforts
R&D Expenses: R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. Net Loss: Net loss widened to $325.1 million in 2023, with a loss per share of $5.15.
Highlights Strategic Progress and Clinical Developments
Anticipates Topline Data from Phase 3 REACH Trial in Q4 2024; Strengthens Cash Position